Alpha-human atrial natriuretic polypeptide-induced rise of plasma and urinary cyclic 3'5'-guanosine monophosphate concentration in human subjects.
Synthetic alpha-hANP was infused into 8 normotensive, euvolemic volunteers to examine the effects on plasma and urinary cyclic-GMP. The dose given and duration of alpha-hANP (0.1 micrograms/kg/min, 20 min) led to the significant diuresis, saliuresis and hypotensive effects in each subject. The mean plasma cyclic-GMP concentration was clearly elevated at 5 min after infusion and attained 8 fold of the mean basal concentrations by the end of infusion. The mean urinary cyclic-GMP excretion rate also showed 3.5 fold increases of the basal excretion rate with synthetic alpha-hANP administration (before loading: 0.69 +/- 0.22 p moles/g creat., after loading: 2.85 +/- 0.28 p moles/g creat.). However, there was no apparent change on plasma or urinary cyclic-AMP during the infusion. The result clearly demonstrated that synthetic alpha-hANP selectively induces the cyclic-GMP in concomitant with the marked diuretic, natriuretic and hypotensive effects in human subjects.
D000328:Adult; D009320:Atrial Natriuretic Factor / Q000494:pharmacology*; D006152:Cyclic GMP / Q000032:analysis* / Q000097:blood / Q000652:urine; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008297:Male; D008875:Middle Aged
D009320:Atrial Natriuretic Factor; D006152:Cyclic GMP